Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive he estimates its therapy ARDS-003 to generate potential revenues from royalties on net sales, milestone and upfront payments of over US$500 million by 2026.
Chamberland says the investigational new drug is designed to dampen the so-called "cytokine storm" and prevent the development of Acute Respiratory Distress Syndrome (ARDS), the life-threatening condition seen in serious coronavirus (COVID-19) cases.
Price: 0.195 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive the group it held a Type B meeting with the FDA for an inhaled THC-based innovative drug for the treatment of chemotherapy-induced nausea and vomiting (CINV). Chamberland says new drug will be part its...
Retail & consumer
Prev article
